pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)
Shanghai Antengene Corporation
Shanghai Antengene Corporation Limited
Shanghai Antengene Corporation patent portfolio — 53 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- SAINT-LAURENT, CN
- Programs
- 3
- Drugs
- 8
- Patents
- 53
Shanghai Antengene Corporation patents
53 pharmaceutical patents indexed for Shanghai Antengene Corporation. 1 expire within 24 months.
Shanghai Antengene Corporation has 53 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 8431543
Chitosan based polymer conjugate and a method for producing the same
granted -
US 8003091
Pharmaceutical compositions comprising purified intact bacterial minicells
granted -
US 7611885
Pharmaceutically compatible method for purifying intact bacterial minicells
granted -
US 7335646
Compositions and methods for regulated protein expression in gut
granted -
US 6033845
Specific diagnostic for feline infectious peritonitis antibodies
expired
Frequently asked questions
How many patents does Shanghai Antengene Corporation have?
53 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Shanghai Antengene Corporation patents expire?
1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.